Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.16 USD
+0.27 (1.00%)
Updated Nov 26, 2024 04:00 PM ET
After-Market: $27.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMVT 27.16 +0.27(1.00%)
Will IMVT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Other News for IMVT
Vertex leads J.P. Morgan's top biotech picks list for 2025
Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc.
Deep Track Capital, LP Reduces Stake in Apellis Pharmaceuticals Inc
3 Best Stocks to Buy Now, 11/21/2024, According to Top Analysts
Immunovant’s IMVT-1402: A Promising Breakthrough for Graves’ Disease with Significant Market Potential